Helai P Mohammad - GlaxoSmithKline, Canc Epigenet Dept, Collegeville, PA 19426 USA

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 92 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Discovery and Characterization of PVTX-321 As a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2- Breast Cancer

Guozhang Xu, Courtney G Havens,Qiaolin Deng, Cassandra Lowenstein,Debangshu Samanta, Brian Vidal, Elham Behshad, Mike Russell,Peter Orth, Cory T Rice, Rakesh Nagilla, Paul Kirchhoff, Zhixiang Chen,Rohan Kalyan Rej, Ranjan Kumar Acharyya, Dimin Wu,Shaomeng Wang, Weihong Zhang, Wenxue Wu, Larry Jolivette,Corey Strickland, Zhihua Sui,Helai P Mohammad, Xuqing Zhang, E Scott Priestley

Journal of medicinal chemistryno. 11 (2025): 11299-11321

Cited0Views0WOSBibtex

Overcoming CK1α Liability in the Discovery of a Series of Isoindolinone Glutarimides As Selective IKZF2 Molecular Glue Degraders

Xuqing Zhang,Qiaolin Deng, Harshil Dhruv, Matthew Tudor, Rakesh Nagilla,Larry J Jolivette, Cory T Rice,Peter Orth, Elham Behshad, Corey O Strickland,Helai P Mohammad, Zhihua Sui, E Scott Priestley

Bioorganic & medicinal chemistry letters (2025): 130263-130263

Cited0Views0WOSBibtex

Discovery and Characterization of a P300-Selective Degrader with Potent Anti-Tumor Activity in CBP Mutant Cancers

Mike R. Russell, Cassandra L. Lowenstein, Xuqing Zhang, Jeremy Roach, Jianing Song,Rakesh Nagilla,Nathan Kendsersky, Shreyas Joshi,Peter Orth,Matt Tudor,Qiaolin Deng,Clemente Aguilar-Bonavides,Elham Behshad, Sudeep Banjade,Zhihua Sui,Corey Strickland,Larry Jolivette,Helai P. Mohammad

Cancer Researchno. 6_Supplement (2024): 6043-6043

Cited0Views0Bibtex

Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders

Zhenwu Li, Lalgudi S. Harikrishnan, Guozhang Xu,Debangshu Samanta, Jose C. Clemente,Lingying Leng, Wenbin Tu, Lin Yang,Liyue Huang,Mi Wang,Shaomeng Wang,Qiaolin Deng,Elham Behshad,Rakesh Nagilla,Peter Orth, Cory Rice,Corey Strickland,Helai P. Mohammad, E. Scott Priestley,Zhihua Sui

JOURNAL OF MEDICINAL CHEMISTRY (2024)

Cited0Views0WOSBibtex

Discovery of Oral SMARCA2 Degraders for the Treatment of SMARCA4 Mutant Tumors

Jose C. Clemente, Lal Harikrishnan, Steve Knight,Debangshu Samanta, Zhenwu Li,Rakesh Nagilla,Nathan Kendsersky, Shreyas Joshi,Peter Orth,Matt Tudor,Qiaolin Deng,Clemente Aguilar-Bonavides,Elham Behshad,Zhihua Sui,Corey Strickland,Larry J. Jolivette,Helai P. Mohammad

Cancer Researchno. 6_Supplement (2024): 6051-6051

Cited1Views0Bibtex

Discovery and Characterization of PVTX-321, an Estrogen Receptor Heterobifunctional Degrader

Courtney G. Havens, Guozhang Xu, Cass Lowenstein,Debangshu Samanta,Brian Vidal,Elham Behshad,Rakesh Nagilla,Mike Russell,Peter Orth,Winston Wu,Larry Jolivette, Scott Priestley,Helai Mohammad,Zhihua Sui

Cancer Researchno. 6_Supplement (2024): 6047-6047

Cited0Views0Bibtex

the Selective IKZF2 Molecular Glue Degrader, PVTX-405, Counters Treg Immune Suppression,shows Significant Tumor Growth Delay As Single Agent and Synergistic Response with Immune Checkpoint Therapies (Icts)

Harshil D. Dhruv,Donna McEachern,Longchuan Bai, Xuqing Zhang, Zhixiang Chen,Rakesh Nagilla,Elham Behshad, Bomie Han,Peter Orth, Rohan Rej,Paul Kirchhoff,Niu Shin,Larry Jolivette,Corey Strickland,Zhihua Sui, Scott Priestley,Shaomeng Wang,Helai Mohammad

Cancer Researchno. 6_Supplement (2024): 2656-2656

Cited0Views0Bibtex

Supplementary Figure 3 from Polycomb CBX7 Promotes Initiation of Heritable Repression of Genes Frequently Silenced with Cancer-Specific DNA Hypermethylation

Helai P. Mohammad,Yi Cai,Kelly M. McGarvey,Hariharan Easwaran,Leander Van Neste,Joyce E. Ohm,Heather M. O'Hagan,Stephen B. Baylin

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn